Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation
- PMID: 12127961
- DOI: 10.1016/s0006-291x(02)00751-9
Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation
Abstract
High levels of Wilms' Tumor 1 (WT1) mRNA have been correlated with poor prognosis in breast cancer patients. However, the function of WT1 protein in breast cancer is not known. We observed that the levels of WT1 protein correlated with the proliferation of breast cancer cells. When the proliferation of breast cancer cells was stimulated by 17beta-estradiol, WT1 protein expression increased. But when the proliferation of breast cancer cells was inhibited by tamoxifen or all-trans retinoic acid (ATRA), WT1 protein expression decreased. We hypothesize that WT1 protein plays a role in regulating breast cancer cell proliferation. Using liposome-incorporated WT1 antisense oligodeoxynucleotides, we found that downregulation of WT1 protein expression led to breast cancer growth inhibition and reduced cyclin D1 protein levels. These results indicate that WT1 protein contributes to breast cancer progression by promoting breast cancer cell proliferation.
Similar articles
-
Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation.Oncogene. 2008 Jan 3;27(1):126-38. doi: 10.1038/sj.onc.1210622. Epub 2007 Jun 25. Oncogene. 2008. PMID: 17599043
-
Inhibition of breast cancer cell growth by the Wilms' tumor suppressor WT1 is associated with a destabilization of beta-catenin.Anticancer Res. 2003 Sep-Oct;23(5A):3575-84. Anticancer Res. 2003. PMID: 14666652
-
HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells.Oncogene. 2005 Feb 24;24(9):1648-52. doi: 10.1038/sj.onc.1208345. Oncogene. 2005. PMID: 15674342
-
The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism.Int J Biol Sci. 2020 Feb 24;16(8):1474-1480. doi: 10.7150/ijbs.39958. eCollection 2020. Int J Biol Sci. 2020. PMID: 32210734 Free PMC article. Review.
-
Cancer immunotherapy targeting Wilms' tumor gene WT1 product.Expert Rev Vaccines. 2005 Aug;4(4):503-12. doi: 10.1586/14760584.4.4.503. Expert Rev Vaccines. 2005. PMID: 16117707 Review.
Cited by
-
shRNA-WT1 Potentiates Anticancer Effects of Gemcitabine and Cisplatin Against B16F10 Lung Metastases In Vitro and In Vivo.In Vivo. 2019 May-Jun;33(3):777-785. doi: 10.21873/invivo.11539. In Vivo. 2019. PMID: 31028197 Free PMC article.
-
Overexpression of WT1 in all molecular subtypes of breast cancer and its impact on survival: exploring oncogenic and tumor suppressor roles of distinct WT1 isoforms.Mol Biol Rep. 2024 Apr 20;51(1):544. doi: 10.1007/s11033-024-09450-4. Mol Biol Rep. 2024. PMID: 38642153
-
Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression.J Neurooncol. 2011 May;103(1):87-102. doi: 10.1007/s11060-010-0374-7. Epub 2010 Sep 4. J Neurooncol. 2011. PMID: 20820871 Free PMC article.
-
Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma.Virchows Arch. 2007 Jul;451(1):27-35. doi: 10.1007/s00428-007-0433-4. Epub 2007 Jun 27. Virchows Arch. 2007. PMID: 17594113
-
Association between WT1 polymorphisms and susceptibility to breast cancer: results from a case-control study in a southwestern Chinese population.Am J Cancer Res. 2015 Feb 15;5(3):1234-50. eCollection 2015. Am J Cancer Res. 2015. PMID: 26046002 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials